(Q36677197)

15 August 2017

1 reference

title

Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors (English)

1 reference

15 August 2017

1 reference

Robert A Beckman

1

1 reference

15 August 2017

Louis M Weiner

series ordinal

2

1 reference

15 August 2017

Hugh M Davis

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

109

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

170-179

1 reference

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

Time-resolved confocal analysis of antibody penetration into living, solid tumor spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

Construction, expression and tumor targeting of a single-chain Fv against human colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

Monoclonal antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Crystal structure of a diabody, a bivalent antibody fragment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Antibodies and their fragments as anti-cancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Drug delivery and transport to solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Slowed diffusion in tumors revealed by microfiberoptic epifluorescence photobleaching

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Microvascular permeability of normal and neoplastic tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Efficient tumor targeting by single-domain antibody fragments of camels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Engineered antibody fragments and the rise of single domains

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Molecular medicine: the writing is on the vessel wall

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Future of monoclonal antibodies in the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Genetic instability in cancer: theory and experiment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22402

7 January 2021

Identifiers

DOI

10.1002/CNCR.22402

1 reference

15 August 2017

1 reference